FMS
Fresenius Medical Care AG & Co. KGaA
There isn't enough reported data to score FMS yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FMS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Stable |
FMS's profitability and cash flow are currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FMS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $38.09 | +76% |
| Fair | 12x | $40.06 | +85% |
| Current | 13x | $21.60 | — |
| Expensive | 16x | $51.64 | +139% |
Historical ranges are pointers, not guarantees.
FMS has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect FMS's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over FMS on the outlook, with more favorable earnings and revenue expectations.
FMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.30 | +21% |
| Q4 2025 | $3.73 | +84% |
| Q3 2025 | $2.72 | +8.8% |
| Q2 2025 | $2.49 | +24% |
| Q1 2025 | $2.34 | +28% |
| Q4 2024 | $2.03 | +7.4% |
| Q3 2024 | $2.50 | +46% |
| Q2 2024 | $2.01 | -11% |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 41% for FMS versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
FMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16B | +195% |
| Q4 2025 | $5.6B | -0.3% |
| Q3 2025 | $5.4B | +2.6% |
| Q2 2025 | $5.3B | +0.5% |
| Q1 2025 | $5.4B | +3.3% |
| Q4 2024 | $5.6B | +1.9% |
| Q3 2024 | $5.3B | -3.6% |
| Q2 2024 | $5.3B | -1.2% |
FMS has the stronger quarterly revenue trend. Revenue is up 195% for FMS versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.9% | +1.1 points |
| Q4 2025 | 12% | +6.6 points |
| Q3 2025 | 9.8% | 0 points |
| Q2 2025 | 8.9% | 0 points |
| Q1 2025 | 6.8% | +1.6 points |
| Q4 2024 | 5.1% | -3.5 points |
| Q3 2024 | 9.7% | +3.2 points |
| Q2 2024 | 8.9% | +1.5 points |
FMS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
FMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2020 | $555.7M | +$1B |
| Q2 2020 | $2.3B | +278% |
FMS and OSCR do not have enough comparable growth data to identify a winner.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
FMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7.7% | -22.4M shares |
| 1 year | -8.4% | -24.6M shares |
| 3 years | -8.4% | -24.6M shares |
| 5 years | -8.2% | -24M shares |
| Available history | -11% | -34.6M shares |
FMS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $862.2M |
| Q4 2025 | $482.3M |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $166.5M |
| Q1 2020 | $240.1M |
| Q4 2019 | $150.3M |
| Q3 2019 | $848.1M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 3.4x | Elevated |
| Q3 2024 | 1.9x | Healthy |
| Q2 2024 | 2.1x | Moderate |
FMS's net debt is about 1.9 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over FMS on leverage, with a lower net debt burden relative to earnings.
FMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 39.7 | Neutral |
FMS's weekly RSI is 43 (neutral) and its Stochastic is 40 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FMS PE vs Healthcare Sector
| Metric | FMS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 69 | 29 | 40 pts above |
FMS is trading at 13x earnings, a 49% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over FMS on valuation relative to its sector.
FMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.3 | 3.1% below |
| 20 week MA | $23.1 | 6.5% below |
| 50 week MA | $23.0 | 6% below |
| 100 week MA | $24.2 | 11% below |
| 200 week MA | $22.6 | 4.3% below |
FMS is in a downtrend: it's below all five of its weekly moving averages, and 4.3% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over FMS on trend strength, trading above more of its moving averages.
FMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.4 | $41.3 | +10% |
| 2021 | $41.3 | $32.1 | -22% |
| 2022 | $32.1 | $16.0 | -50% |
| 2023 | $16.0 | $20.8 | +30% |
| 2024 | $20.8 | $23.0 | +10% |
| 2025 | $23.0 | $24.1 | +5% |
| 2026 YTD | $24.1 | $21.6 | -10% |
FMS has finished higher in four of the last six years. It's down 10% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FMS on returns for 2026, with the stronger performance.